Range
36.54 - 38.32
Vol / Avg.
87.2K/143.3K
Div / Yield
-
52 Wk
25.71 - 88.8
Mkt Cap
877.8M
Payout Ratio
-
Open
36.8
P/E
-
EPS
-0.68
Shares
23.3M
Outstanding
23.3M
Total Float
12.8M
Benzinga - Jun 24, 2021, 5:08AM
Benzinga - Jun 23, 2021, 3:48PM
Benzinga - Jun 22, 2021, 4:21PM
Benzinga - Jun 11, 2021, 8:03AM
Benzinga - May 25, 2021, 8:10AM
Benzinga - May 14, 2021, 8:40AM
Benzinga - May 6, 2021, 4:30PM
Benzinga - May 3, 2021, 4:53PM
Benzinga - Apr 30, 2021, 12:14PM
Benzinga - Mar 25, 2021, 8:05AM
Benzinga - Mar 5, 2021, 8:03AM
Benzinga - Mar 5, 2021, 8:02AM
Benzinga - Dec 21, 2020, 8:03AM
Benzinga - Dec 8, 2020, 6:42AM
Benzinga - Dec 8, 2020, 6:19AM
Benzinga - Nov 13, 2020, 8:43AM
Benzinga - Nov 13, 2020, 5:34AM
load more
Sector: Health Care.Industry: Biotechnology
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-12
REV
Q1 2021Est.ActualSurprise
EPS-0.580-0.680 -0.1000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
KROSKeros Therapeutics0%877.8M

Keros Therapeutics Frequently Asked Questions

Q

How do I buy Keros Therapeutics (KROS) stock?

A

You can purchase shares of Keros Therapeutics (NASDAQ: KROS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Keros Therapeutics's (KROS) competitors?

A

Other companies in Keros Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Humanigen (NASDAQ:HGEN), Immatics (NASDAQ:IMTX), Mesoblast (NASDAQ:MESO) and Silence Therapeutics (NASDAQ:SLN).

Q

What is the target price for Keros Therapeutics (KROS) stock?

A

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by SVB Leerink on December 8, 2020. The analyst firm set a price target for 80.00 expecting KROS to rise to within 12 months (a possible 112.31% upside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Keros Therapeutics (KROS)?

A

The stock price for Keros Therapeutics (NASDAQ: KROS) is $37.68 last updated Today at 8:00:01 PM.

Q

Does Keros Therapeutics (KROS) pay a dividend?

A

There are no upcoming dividends for Keros Therapeutics.

Q

When is Keros Therapeutics (NASDAQ:KROS) reporting earnings?

A
Keros Therapeutics’s Q2 earnings are confirmed for after-market on August 12, 2021.
Q

Is Keros Therapeutics (KROS) going to split?

A

There is no upcoming split for Keros Therapeutics.

Q

What sector and industry does Keros Therapeutics (KROS) operate in?

A

Keros Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.